AmerisourceBergen Corporation (ABC) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AmerisourceBergen Corporation (ABC) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 45/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026AmerisourceBergen Corporation (ABC) Resumen de Asistencia Médica y Tuberías
AmerisourceBergen Corporation is a global pharmaceutical distributor providing brand-name and generic drugs, healthcare products, and related services. With a focus on pharmaceutical distribution and integrated manufacturer services, the company serves a diverse customer base, including hospitals, pharmacies, and veterinary practices, navigating a complex regulatory landscape.
Tesis de Inversión
AmerisourceBergen presents a stable investment opportunity within the healthcare sector, driven by its essential role in pharmaceutical distribution. The company's consistent revenue stream is supported by long-term contracts and a diversified customer base. A key value driver is the increasing demand for specialty pharmaceuticals and related services, where AmerisourceBergen has established a strong presence. However, investors may want to evaluate the relatively low profit margin of 0.5% and the potential impact of regulatory changes on drug pricing and distribution. The company's beta of 0.56 suggests lower volatility compared to the overall market. The dividend yield of 0.66% provides a modest income stream.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $36.15 billion, reflecting its significant presence in the pharmaceutical distribution market.
- P/E ratio of 41.82, indicating investor expectations for future earnings growth.
- Gross margin of 3.3%, highlighting the competitive pricing environment in the pharmaceutical distribution industry.
- Dividend yield of 0.66%, providing a modest return for investors.
- Beta of 0.56, suggesting lower volatility compared to the broader market.
Competidores y Pares
Fortalezas
- Extensive distribution network
- Strong relationships with pharmaceutical manufacturers
- Comprehensive service offerings
- Scale and purchasing power
Debilidades
- Low profit margin
- Dependence on pharmaceutical manufacturers
- Exposure to regulatory changes
- High debt levels
Catalizadores
- Ongoing: Increasing demand for specialty pharmaceuticals, driving growth in related services.
- Ongoing: Strategic partnerships with pharmaceutical manufacturers to enhance product access and distribution.
- Upcoming: Potential acquisitions of complementary businesses to expand service offerings and geographic reach.
- Ongoing: Investments in technology and infrastructure to improve supply chain efficiency.
Riesgos
- Potential: Increased competition from other pharmaceutical distributors and manufacturers.
- Ongoing: Drug pricing pressures and regulatory changes impacting reimbursement rates.
- Potential: Economic downturn affecting demand for healthcare products and services.
- Ongoing: Dependence on key pharmaceutical manufacturers for product supply.
Oportunidades de crecimiento
- Expansion of Specialty Pharmaceutical Services: The increasing demand for specialty pharmaceuticals, particularly in oncology and immunology, presents a significant growth opportunity for AmerisourceBergen. By expanding its services for specialty drug manufacturers and providers, including data analytics and patient support programs, the company can capture a larger share of this high-growth market. The specialty pharmaceutical market is projected to reach $400 billion by 2026, offering substantial revenue potential.
- Strategic Acquisitions and Partnerships: AmerisourceBergen can pursue strategic acquisitions and partnerships to expand its service offerings and geographic reach. Acquiring companies with complementary capabilities, such as specialty pharmacies or healthcare technology providers, can enhance its competitive position and drive revenue growth. Partnerships with pharmaceutical manufacturers can also strengthen its supply chain and improve access to innovative therapies. These initiatives can be implemented within the next 1-3 years.
- Growth in Animal Health Market: The animal health market is experiencing steady growth, driven by increasing pet ownership and rising demand for animal healthcare products. AmerisourceBergen's Other segment, which includes animal health products and services, can capitalize on this trend by expanding its product portfolio and distribution network. The global animal health market is expected to reach $75 billion by 2028, providing a significant growth opportunity.
- Enhancement of Supply Chain Efficiency: Improving supply chain efficiency can reduce costs and enhance customer satisfaction. AmerisourceBergen can invest in technology and infrastructure to optimize its distribution network, improve inventory management, and streamline order processing. By leveraging data analytics and automation, the company can identify and address inefficiencies in the supply chain, leading to improved profitability and competitiveness. This is an ongoing opportunity.
- Expansion of Integrated Manufacturer Services: The demand for integrated manufacturer services, such as clinical trial support and product commercialization, is growing as pharmaceutical companies seek to outsource non-core activities. AmerisourceBergen can expand its service offerings in this area to capture a larger share of the market. By providing comprehensive solutions that support the entire product lifecycle, the company can become a strategic partner for pharmaceutical manufacturers and drive long-term revenue growth. This expansion can occur over the next 2-5 years.
Oportunidades
- Expansion of specialty pharmaceutical services
- Strategic acquisitions and partnerships
- Growth in animal health market
- Enhancement of supply chain efficiency
Amenazas
- Increased competition
- Drug pricing pressures
- Regulatory changes
- Economic downturn
Ventajas competitivas
- Extensive distribution network: AmerisourceBergen has a well-established distribution network that reaches a wide range of healthcare providers.
- Strong relationships with pharmaceutical manufacturers: The company has long-standing relationships with major pharmaceutical manufacturers, ensuring access to a wide range of products.
- Comprehensive service offerings: AmerisourceBergen offers a comprehensive suite of services, including pharmaceutical distribution, pharmacy management, and integrated manufacturer services.
- Scale and purchasing power: The company's scale and purchasing power allow it to negotiate favorable pricing with manufacturers and achieve economies of scale.
Acerca de ABC
AmerisourceBergen Corporation, established in 2001 and headquartered in Conshohocken, Pennsylvania, is a leading global healthcare solutions provider focused on pharmaceutical distribution and related services. The company operates through two primary segments: Pharmaceutical Distribution and Other. The Pharmaceutical Distribution segment distributes a wide range of pharmaceutical products, including brand-name and generic drugs, over-the-counter healthcare products, and home healthcare supplies. This segment serves various healthcare providers, such as acute care hospitals, retail pharmacies, mail-order pharmacies, medical clinics, and long-term care facilities. AmerisourceBergen also offers pharmacy management, staffing, and consulting services, along with supply management software and packaging solutions. The Other segment provides integrated manufacturer services, including clinical trial support, product post-approval services, and commercialization support. Additionally, this segment offers specialty transportation and logistics services for the biopharmaceutical industry and distributes pharmaceuticals, vaccines, and other products to the companion and production animal markets. AmerisourceBergen's extensive distribution network and comprehensive service offerings position it as a key player in the pharmaceutical supply chain, connecting manufacturers and healthcare providers to improve patient access to medications and healthcare solutions.
Qué hacen
- Distributes brand-name and generic pharmaceuticals to healthcare providers.
- Provides over-the-counter healthcare products and home healthcare supplies.
- Offers pharmacy management, staffing, and consulting services.
- Develops and implements supply management software for healthcare providers.
- Provides packaging solutions to institutional and retail healthcare providers.
- Distributes plasma and other blood products, injectable pharmaceuticals, and vaccines.
- Offers data analytics and outcomes research for biotechnology and pharmaceutical manufacturers.
- Provides integrated manufacturer services, including clinical trial support and product commercialization.
Modelo de Negocio
- Generates revenue through the distribution of pharmaceutical products to healthcare providers.
- Provides value-added services, such as pharmacy management and consulting, to generate additional revenue.
- Offers integrated manufacturer services to pharmaceutical companies, creating a diversified revenue stream.
Contexto de la Industria
AmerisourceBergen operates within the medical distribution industry, a sector characterized by consolidation and increasing regulatory scrutiny. The industry is driven by the growing demand for pharmaceuticals, driven by an aging population and advancements in medical treatments. Key trends include the rise of specialty pharmaceuticals, the increasing importance of supply chain efficiency, and the growing focus on patient outcomes. AmerisourceBergen competes with other major distributors and faces pressure from manufacturers seeking to control distribution channels. The industry is subject to regulations related to drug pricing, safety, and distribution practices.
Clientes Clave
- Acute care hospitals and health systems
- Independent and chain retail pharmacies
- Mail order pharmacies
- Medical clinics
- Long-term care and alternate site pharmacies
Finanzas
Gráfico e información
Precio de la acción de AmerisourceBergen Corporation (ABC): Price data unavailable
Últimas noticias
-
Earnings Scheduled For August 2, 2023
benzinga · 2 ago 2023
-
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2022
benzinga · 26 may 2022
-
Stocks That Hit 52-Week Highs On Wednesday
· 21 abr 2021
-
Stocks That Hit 52-Week Highs On Friday
· 8 ene 2021
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ABC.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ABC.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ABC en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Steven H. Collis
Chairman, President and Chief Executive Officer
Steven H. Collis has served as Chairman, President & CEO of AmerisourceBergen since 2011. Prior to this, he held various leadership positions within the company, including President and Chief Operating Officer. His extensive experience in the pharmaceutical industry spans over two decades, providing him with a deep understanding of the market dynamics and challenges. He is known for his strategic vision and focus on innovation.
Historial: Under Steven H. Collis's leadership, AmerisourceBergen has experienced significant growth and expansion, solidifying its position as a leading global healthcare solutions provider. He has overseen key acquisitions and strategic initiatives that have enhanced the company's service offerings and geographic reach. Collis has also been instrumental in driving innovation and improving operational efficiency, contributing to the company's financial performance.
ABC Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar ABC?
AmerisourceBergen Corporation (ABC) actualmente tiene una puntuación IA de 45/100, indicando puntuación baja. Fortaleza clave: Extensive distribution network. Riesgo principal a monitorear: Potential: Increased competition from other pharmaceutical distributors and manufacturers.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ABC?
ABC actualmente puntúa 45/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ABC?
Los precios de ABC se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ABC?
La cobertura de analistas para ABC incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ABC?
Las categorías de riesgo para ABC incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Increased competition from other pharmaceutical distributors and manufacturers.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ABC?
La relación P/E para ABC compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ABC sobrevalorada o infravalorada?
Determinar si AmerisourceBergen Corporation (ABC) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ABC?
AmerisourceBergen Corporation (ABC) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.